264 related articles for article (PubMed ID: 30043557)
1. Should omalizumab be used in severe asthma/COPD overlap?
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Ricci A; Paggiaro P
J Biol Regul Homeost Agents; 2018; 32(4):755-761. PubMed ID: 30043557
[TBL] [Abstract][Full Text] [Related]
2. Challenges in the management of asthma associated with smoking-induced airway diseases.
Thomson NC
Expert Opin Pharmacother; 2018 Oct; 19(14):1565-1579. PubMed ID: 30196731
[TBL] [Abstract][Full Text] [Related]
3. [OMALIZUMAB RESCUED A ASTHMA-COPD OVERLAP SYNDROME PATIENT FROM A STATUS ASTHMATICS UNDER THE ICU MANAGEMENT].
Gamo S; Iijima H; Seki Y; Horaguchi R; Suda Y; Shindoh Y
Arerugi; 2016 Jul; 65(7):937-41. PubMed ID: 27545060
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab treatment in asthma-COPD overlap syndrome.
Tat TS; Cilli A
J Asthma; 2016 Dec; 53(10):1048-50. PubMed ID: 27144514
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO.
Hanania NA; Chipps BE; Griffin NM; Yoo B; Iqbal A; Casale TB
J Allergy Clin Immunol; 2019 Apr; 143(4):1629-1633.e2. PubMed ID: 30576755
[No Abstract] [Full Text] [Related]
6. Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease.
Pérez de Llano L; Cosío BG; Miravitlles M; Plaza V;
Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):198-204. PubMed ID: 29229474
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic approaches of asthma and COPD overlap.
Kondo M; Tamaoki J
Allergol Int; 2018 Apr; 67(2):187-190. PubMed ID: 28965921
[TBL] [Abstract][Full Text] [Related]
8. Investigating Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap (ACO): A Scoping Review.
Mostafavi-Pour-Manshadi SM; Naderi N; Barrecheguren M; Dehghan A; Bourbeau J
COPD; 2018; 15(4):377-391. PubMed ID: 30067401
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD.
Maltby S; Gibson PG; Powell H; McDonald VM
Chest; 2017 Jan; 151(1):78-89. PubMed ID: 27742181
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis.
Arasi S; Costa S; Magazzù G; Ieni A; Crisafulli G; Caminiti L; Chiera F; Vaccaro M; Del Giudice MM; Pajno GB
Ital J Pediatr; 2016 Mar; 42():32. PubMed ID: 27000314
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
Yalcin AD; Celik B; Yalcin AN
Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):253-6. PubMed ID: 27121601
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
Barnes PJ
J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
[TBL] [Abstract][Full Text] [Related]
13. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
[No Abstract] [Full Text] [Related]
14. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
Tortajada-Girbés M; Bousquet R; Bosque M; Carrera Martínez JJ; Ibáñez MD; Moreira A; Nieto A; Plaza AM; Rivas C; Requena G; Sánchez-Solis M; Tabar A; Torres-Borrego J; Zapatero L
Expert Rev Respir Med; 2018 Sep; 12(9):745-754. PubMed ID: 30141696
[TBL] [Abstract][Full Text] [Related]
15. Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review protocol.
Mostafavi-Pour-Manshadi SM; Naderi N; Barrecheguren M; Dehghan A; Bourbeau J
BMJ Open; 2017 Dec; 7(12):e018954. PubMed ID: 29273668
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap.
Takayama Y; Ohnishi H; Ogasawara F; Oyama K; Kubota T; Yokoyama A
Int J Chron Obstruct Pulmon Dis; 2018; 13():2525-2532. PubMed ID: 30174422
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma.
Frix AN; Schleich F; Paulus V; Guissard F; Henket M; Louis R
Biochem Pharmacol; 2020 Sep; 179():113944. PubMed ID: 32240649
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
19. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
Kupryś-Lipińska I; Molińska K; Kuna P
Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
[TBL] [Abstract][Full Text] [Related]
20. Novel targets of omalizumab in asthma.
Sattler C; Garcia G; Humbert M
Curr Opin Pulm Med; 2017 Jan; 23(1):56-61. PubMed ID: 27798419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
